Sage shares soar after oral postpartum depression treatment succeeds in trial

Sage Therapeutics Inc said on Monday its oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared to a placebo in a late-stage study, sending its shares up 33 percent.

from Reuters: Health News https://reut.rs/2AByLVw